Truist Financial Corp Innoviva, Inc. Transaction History

Truist Financial Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 17, 2023	BUY	$11.8 - $13.78 $397,966 - $464,744	33,726 New	33,726 $446,000
Q2 2022 Jul 22, 2022	BUY	$14.32 - $19.88 $274,457 - $381,020	19,166 New	19,166 $283,000
Q3 2021 Nov 05, 2021	SELL	$13.06 - $17.24 $424,567 - $560,455	-32,509 Closed	0 $0
Q4 2020 Nov 19, 2021	SELL	$9.33 - $12.48 $42,899 - $57,383	-4,598 Reduced 12.39%	32,509 $402,000
Q4 2020 Feb 18, 2021	BUY	$9.33 - $12.48 $41,210 - $55,124	4,417 Added 13.51%	37,107 $459,000
Q3 2020 Nov 13, 2020	SELL	$10.33 - $14.49 $3,584 - $5,028	-347 Reduced 1.05%	32,690 $341,000
Q2 2020 Aug 14, 2020	BUY	$11.49 - $15.26 $2,665 - $3,540	232 Added 0.71%	33,037 $462,000
Q1 2020 May 15, 2020	SELL	$8.11 - $15.23 $23,178 - $43,527	-2,858 Reduced 8.01%	32,805 $386,000
Q4 2019 Feb 14, 2020	BUY	$10.28 - $14.38 $366,615 - $512,833	35,663 New	35,663 $505,000

227

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.24B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.